Gilead Sciences | Kısa Vadeli Yükümlülükler



Current Liabilities Değişiklik Tarih
AbbVie USD 38.75B 4.31B 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
Glaxosmithkline GBP 21.7B 238M 2024-12
Incyte USD 1.64B 140.2M 2024-12
J&J USD 50.32B 1.44B 2024-12
Merck USD 28.42B 1.17B 2024-12
Moderna USD 2.21B 5M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Sanofi 30.03B 5.82B 2024-06
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
United Therapeutics USD 738.1M 135.3M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Gilead Sciences Kısa Vadeli Yükümlülükler - Akım değerleri, tarihsel veriler, tahminler, istatistikler, grafikler ve ekonomik takvim - Mar 2025.